Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | CCR1 | P32246 | 5/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21854149 | 0.86 | CAPN1 (0.51) | DCAF1CAPN1 | |
| SCHEMBL20027914 | 0.84 | DCAF1 (0.48) | DCAF1PYGLCAPN1 | |
| SCHEMBL20028717 | 0.82 | DCAF1 (0.50) | DCAF1PYGLCCR1CNR1F2 | |
| SCHEMBL22896923 | 0.80 | PYGL (0.41) | DCAF1PYGLCCR1CNR1CAPN1 | |
| SCHEMBL20027817 | 0.80 | PYGL (0.41) | DCAF1PYGLCCR1CNR1CAPN1 | |
| SCHEMBL22897214 | 0.79 | DCAF1 (0.51) | DCAF1PYGLCNR1F2F10 | |
| SCHEMBL22897243 | 0.79 | DCAF1 (0.51) | DCAF1PYGLCTSL | |
| SCHEMBL20027718 | 0.79 | DCAF1 (0.51) | DCAF1PYGLCTSL | |
| SCHEMBL20028606 | 0.79 | PYGL (0.43) | DCAF1PYGLMAPK1CCR1CNR1 | |
| SCHEMBL20027902 | 0.78 | DCAF1 (0.52) | DCAF1PYGLF2F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | DCAF1 3091/4885PYGL 925/4885MAPK1 3457/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | DCAF1 3598/4885PYGL 668/4885MAPK1 3624/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | DCAF1 3091/4885PYGL 925/4885MAPK1 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.